‘Diversified’ gut-brain axis company Kallyope heading to clinic with $112M series C

Kallyope chooses obesity, IBD for its first two gut-restricted small molecule programs

With what CEO Nancy Thornberry described as a breadth of options spanning multiple therapeutic areas, gut-brain axis company Kallyope will use its new $112 million series C round to bring its first two small molecule programs into the clinic to treat obesity and inflammatory bowel disease.

All of

Read the full 470 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE